Product Earth

ONE DOSE. THREE MONTHS OF EFFECT?

A Phase 3 trial of Definium Therapeutics’ L*D-based treatment DT120 has produced striking results for people with generalized anxiety disorder.

214 people received either a single 100µg dose of DT120 or placebo.

After 12 weeks, anxiety scores had fallen 11.6 points with DT120 vs 6.2 with placebo — a statistically significant 5.4-point difference.

Improvements were already visible within 48 hours and were sustained throughout the 12-week study.

If a second Phase 3 trial, due to report in September, confirms these findings, L*D could move another step closer to becoming a prescription treatment for anxiety.

Source: Reuters, Kamal Choudhury, Definium says L*D-based pill reduces anxiety in late-stage study, 12 August 2026.

Additional source: Definium Therapeutics Phase 3 Voyage results.

*D

We’ve all been there…🍃

Take a Breath… Take a break.🍃

Another reason cannabis access matters. 🌿
New research from the University of Georgia found that medical cannabis laws were associated with around 7% fewer health-related workplace absences.

The findings add to the growing conversation around cannabis, health and quality of life — and why access to medical cannabis matters.

The evidence is growing. The conversation needs to keep moving.



The study was co-authored by UGA Associate Professor Patryk Babiarz and published in June 2026

Could cannabinoids be changing the conversation around autism? 🌿

New clinical research into NTI164 has produced some seriously interesting results.

In a randomised, double-blind, placebo-controlled trial involving children and adolescents with moderate-to-severe ASD, researchers reported improvements across multiple areas, including:

🧠 Social responsiveness & communication
🧩 Everyday functioning
💭 Emotional regulation & anxiety
❤️ Behavioural symptoms
👨‍👩‍👧 Family quality of life

And importantly, NTI164 was reported to be safe and well tolerated, with no serious adverse events during the study.

The study was relatively small and lasted just 8 weeks, so larger trials are needed to confirm the findings.

But with a Phase III trial now being developed, the research is moving forward.

The science is evolving. The conversation is changing. 🌱



Source: https://www.neurotherapeuticsjournal.org/article/S1878-7479(26)00203-5/fulltext

They can outlaw the plant.
They can’t outlaw the truth.

Some we know. Many we’ve never met.

Thank you for being here, for following, sharing, commenting and supporting what we do.🙏🍃

We’ll keep elevating.🍃

No noise, just good energy.

Portugal exported 66.3 tonnes of cannabis for medicinal purposes in just six months. 🇵🇹🌿

Between January and June 2026, exports reached 66,305 kg — already 83% of the total exported during the whole of 2025.
Germany, Spain and Denmark were among the leading destinations.

Portugal’s medicinal cannabis industry continues to grow rapidly — but the scale of exports also raises an important question: how much of this sector is actually benefiting patients at home?

Source: INFARMED



“Cannabis isn’t a gateway — it’s a way out.”

For years, cannabis was blamed as a “gateway drug.” But for many, it’s been the opposite — a path away from addiction, chronic pain, and dependency on harmful medications.

Used responsibly, it’s helped people manage:
- PTSD
- Opioid withdrawal
- Anxiety & insomnia
- Chronic conditions where other treatments failed

The narrative is shifting - from fear to facts, from stigma to science.